Cyclophosphamide clinical trials
Also written Cytoxan, Endoxan, cytophosphane and NSC-26271.
Its developmentBy 28 companies, company by company70 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.Related medicines add 6 studies
Counted the way a researcher would: Cyclophosphamide with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Cyclophosphamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Cyclophosphamide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Nov 1959 · CYTOXAN · NDA 012141 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
1,525 studies that test it; most in 2007 (67); 5 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 5 |
| 1991 | 8 |
| 1992 | 5 |
| 1993 | 9 |
| 1994 | 10 |
| 1995 | 14 |
| 1996 | 21 |
| 1997 | 14 |
| 1998 | 35 |
| 1999 | 35 |
| 2000 | 33 |
| 2001 | 31 |
| 2002 | 42 |
| 2003 | 39 |
| 2004 | 48 |
| 2005 | 57 |
| 2006 | 59 |
| 2007 | 67 |
| 2008 | 61 |
| 2009 | 58 |
| 2010 | 55 |
| 2011 | 52 |
| 2012 | 41 |
| 2013 | 57 |
| 2014 | 54 |
| 2015 | 67 |
| 2016 | 58 |
| 2017 | 64 |
| 2018 | 47 |
| 2019 | 54 |
| 2020 | 47 |
| 2021 | 55 |
| 2022 | 40 |
| 2023 | 58 |
| 2024 | 31 |
| 2025 | 41 |
| 2026 | 53 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 110 · Other 1,428
National Cancer Institute (NCI) (73) · M.D. Anderson Cancer Center (71) · Fred Hutchinson Cancer Center (54) · Children's Oncology Group (53) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (46) · Memorial Sloan Kettering Cancer Center (44) · St. Jude Children's Research Hospital (42) · City of Hope Medical Center (37)
Often tested with
Tested in the same studies.
Fludarabine (394) · Doxorubicin (271) · Etoposide (203) · Vincristine (202) · Rituximab (162) · Prednisone (150) · Dexamethasone (129) · Methotrexate (117)
Related medicines
As reviewed, each with the page that says it.
- One of Alkylating agents source
- One of Immunosuppressive Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 24 phase 3 studies under way
Cyclophosphamide is the comparator. A study of two new drugs counts under both.
- 3Cytarabine · The Affiliated People's Hospital of Ningbo University, University of Birmingham · next primary completion Dec 2026
- 3Carboplatin · Fudan University · next primary completion Jun 2029
- 2Lenalidomide · The Lymphoma Academic Research Organisation, Ruijin Hospital · next primary completion Nov 2028
- 2Ibrutinib · National Cancer Institute (NCI), University College, London · next primary completion Mar 2030
- 2Rituximab · University Hospital, Rouen, University College, London · next primary completion Mar 2027
- 2Paclitaxel · Fudan University, Weiguo Lv
- 2Etoposide · The Affiliated People's Hospital of Ningbo University · next primary completion Dec 2026
- 1Datopotamab deruxtecan · AstraZeneca · next primary completion Nov 2028
Reaching primary completion within a year · 110, 9 in phase 3
Studies that test Cyclophosphamide, phase 3 first.
- Nov 2026High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Phase 3 · Gustave Roussy, Cancer Campus, Grand Paris
- Nov 2026Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)Phase 3 · Haukeland University Hospital
- Dec 2026Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast CancerPhase 2/3 · Hebei Medical University Fourth Hospital
- Dec 2026Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)Phase 3 · Children's Cancer Group, China
- Dec 2026First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)Phase 3 · State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
- Jun 2027A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Phase 3 · Genmab
- Sep 2027Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)Phase 3 · Fudan University
- Sep 2027A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPhase 3 · National Cancer Institute (NCI)
- Oct 2027PPI Versus Histamine Antagnists as Adjuvant to ChemotherapyPhase 3 · Sherief Abd-Elsalam
- Nov 2026Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLLPhase 1/2 · Medical University of South Carolina
Studies
Open first, then newest update. How each study uses Cyclophosphamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 1,538
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07524530Written as Cyclophosphamide
- BrECADD Therapy in Stage 2 B-IV Hodgkin LymphomaRecruitingPhase 2University of MiamiNCT07002216Written as Cyclophosphamide
- T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies.Not yet recruitingPhase 1St. Jude Children's Research HospitalNCT07941531Written as Cyclophosphamide
- GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT05003895Written as Cyclophosphamide
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04002947Written as CHOP
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaRecruitingPhase 2/3National Cancer Institute (NCI)NCT07724457Written as Cyclophosphamide
- Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic LymphomaRecruitingPhase 1City of Hope Medical CenterNCT07758673Written as Cyclophosphamide
- Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline TherapyRecruitingPhase 2M.D. Anderson Cancer CenterNCT06083844Written as Cyclophosphamide
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410Written as Cyclophosphamide
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06058377Written as Cyclophosphamide
- Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade GliomaRecruitingPhase 1Beijing BiotechNCT07480941Written as Cyclophosphamide
- Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial CarcinomaRecruitingPhase 1Beijing BiotechNCT07492628Written as Cyclophosphamide
- Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ CancerRecruitingPhase 1/2Beijing BiotechNCT07551362Written as Cyclophosphamide
- Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaRecruitingPhase 1Beijing BiotechNCT07551336Written as Cyclophosphamide
- Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseRecruitingPhase 2St. Jude Children's Research HospitalNCT07616154Written as Cyclophosphamide 50mg
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationRecruitingPhase 1/2National Cancer Institute (NCI)NCT05436418Written as Cyclophosphamide
- Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological MalignanciesRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT07193420Written as Cyclophosphamide 35mg/kg/day
- Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney CancerNot yet recruitingPhase 2Beth Israel Deaconess Medical CenterNCT07925333Written as Cyclophosphamide
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesRecruitingPhase 1/2National Cancer Institute (NCI)NCT05327023Written as Cyclophosphamide
- Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic MalignanciesRecruitingPhase 1/2National Cancer Institute (NCI)NCT04959175Written as Cyclophosphamide
See all 1,538 studies that test Cyclophosphamide →
Given beside what is tested · 1,497 — Cyclophosphamide is usual care or a partner of the new treatment
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingPhase 1National Cancer Institute (NCI)NCT04301076Written as Cyclophosphamide
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as Cyclophosphamide
- A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLERecruitingPhase 1/2AstraZenecaNCT06897930Written as Cyclophosphamide
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten WorseRecruitingPhase 1/2National Cancer Institute (NCI)NCT07437963Written as Cyclophosphamide
- Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 1National Cancer Institute (NCI)NCT07572136Written as Cyclophosphamide
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT07892027Written as Cyclophosphamide
- BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia PatientsRecruitingPhase 2Ruijin HospitalNCT07301138Written as Cyclophosphamide
- Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK StudyRecruitingPhase 2AIDS Malignancy ConsortiumNCT07662928Written as Cyclophosphamide
- Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual TreatmentRecruitingPhase 1Kite, A Gilead CompanyNCT07304154Written as Cyclophosphamide
- To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07903506Written as Cyclophosphamide
- Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk DiseaseRecruitingPhase 2St. Jude Children's Research HospitalNCT06023641Written as Cyclophosphamide
- Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/LymphomaRecruitingPhase 1John ReneauNCT04848064Written as Cyclophosphamide
- IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT07672483Written as Cyclophosphamide
- Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic LeukemiaNot yet recruitingPhase 1Medical University of South CarolinaNCT07896213Written as Cyclophosphamide
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06890884Written as Cyclophosphamide
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06717347Written as Cyclophosphamide
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07634471Written as Cyclophosphamide
- IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate CancerNot yet recruitingPhase 1Fred Hutchinson Cancer CenterNCT07803653Written as Cyclophosphamide
- Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingPhase 1/2University of Michigan Rogel Cancer CenterNCT07932730Written as Cyclophosphamide
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of ImmunityRecruitingPhase 2National Cancer Institute (NCI)NCT04339777Written as Cyclophosphamide (Cytoxan)
Showing 20 of 1,497.
As the comparator · 124 — what is tested is compared with Cyclophosphamide
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06966700Written as Cyclophosphamide
- Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney FailureRecruitingPhase 2Eastern Cooperative Oncology GroupNCT07085728Written as Cyclophosphamide
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06797635Written as Cyclophosphamide
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06091254Written as Cyclophosphamide
- A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter TransformationRecruitingPhase 2German CLL Study GroupNCT07917780Written as Cyclophosphamide
- Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain AmyloidosisNot yet recruitingPhase 3Regeneron PharmaceuticalsNCT07901725Written as Cyclophosphamide
- Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.RecruitingPhase 2Swiss Cancer InstituteNCT07593482Written as Cyclophosphamide
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)RecruitingPhase 3Incyte CorporationNCT06615050Written as Cyclophosphamide
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS TumorsRecruitingPhase 2Medical University of ViennaNCT01356290Written as Cyclophosphamide
- Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell TransplantationRecruitingPhase 2University of NebraskaNCT06799195Written as High-dose Cyclophosphamide
- TCb vs EC-T in High Risk ER+/HER2- Breast CancerRecruitingPhase 3Fudan UniversityNCT05901428Written as Cyclophosphamide
- Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) AmyloidosisNot yet recruitingPhase 3AbbVieNCT07793422Written as Cyclophosphamide
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaNot yet recruitingPhase 3Ruijin HospitalNCT07719855Written as Cyclophosphamide
- Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in ChildrenNot yet recruitingNot applicableNanfang Hospital, Southern Medical UniversityNCT07675291Written as Cyclophosphamide
- A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)RecruitingPhase 3CelgeneNCT06911502Written as Cyclophosphamide
- Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyRecruitingPhase 2University of BirminghamNCT05848765Written as Cyclophosphamide
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung DiseaseRecruitingPhase 4Tongji HospitalNCT07077486Written as Cyclophosphamide (CYC)
- Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer (EBC)RecruitingPhase 2Hebei Medical University Fourth HospitalNCT06107673Written as Cyclophosphamide injection
- Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for LymphomaRecruitingPhase 3The Affiliated People's Hospital of Ningbo UniversityNCT06520163Written as CHOP
- Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT05929768Written as Cyclophosphamide
Showing 20 of 124.
What changed recently
From the registry's own updates since Oct 19, 2026.
Started recruiting4
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaNov 17, 2026NCT07724457
- Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic LymphomaNov 13, 2026NCT07758673
- Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological MalignanciesNov 10, 2026NCT07193420
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLOct 20, 2026NCT07297914
Stopped2
- Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaSuspendedNov 16, 2026NCT05052528
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)TerminatedOct 19, 2026NCT05600426
Newly registered4
- T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies.Nov 17, 2026NCT07941531
- Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney CancerNov 9, 2026NCT07925333
- Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective StudyNov 2, 2026NCT07908888
- A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.Oct 28, 2026NCT07900516
Codes
What other systems call Cyclophosphamide · ClinicalTrials.gg INT007282
- MeSH (NLM) D003520CyclophosphamideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 8N3DW7272PCYCLOPHOSPHAMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 3002One source FDA
- Wikidata Q27106287cyclophosphamide hydrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C405CyclophosphamideOne source FDA
- DrugBank DBSALT001814One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D003520 | Cyclophosphamide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 8N3DW7272P | CYCLOPHOSPHAMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3002 | — | One source FDA |
| Wikidata | Q27106287 | cyclophosphamide hydrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C405 | Cyclophosphamide | One source FDA |
| DrugBank | DBSALT001814 | — | One source Wikidata |
Also registered as cyclophosphamide anhydrous (UNII 6UXW23996M · RxNorm 1545988).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.